Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Sponsor: Alberta Health services
Summary
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2023-02-01
Completion Date
2027-01-01
Last Updated
2023-01-05
Healthy Volunteers
No
Conditions
Interventions
68Ga-HA-DOTATATE PET/CT imaging
Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients. * After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans. * The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results.
Locations (1)
Foothills Medical Center 1403 29 St NW
Calgary, Alberta, Canada